Mevion & C-RAD integrate for better treatment in proton therapy
Category: #health  By Paroma Bhattacharya  Date: 2019-08-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Mevion & C-RAD integrate for better treatment in proton therapy
  • C-RAD to offer a specific version of Catalyst System named Catalyst PT in proton therapy.
  • Catalyst PT would be especially used for thoracic tumor indications.

Mevion Medical Systems® and C-RAD reportedly announced the combination of the MEVION S250i Proton Therapy System® & C-RAD Catalyst PT™. The combination of these substances supports a continuous workflow with uninterrupted patient monitoring and surface tracking through setup and treatment.

C-RAD provides a specific version of Catalyst System to be utilized in particle and proton therapy- Catalyst PT, based on Catalyst software and technology.

Maastro Proton Therapy, consisting of MEVION 250i Proton Therapy System along with C-RAD unveiled a strategic agreement in the previous year for installing Catalyst PT at its center. C-RAD and Mevion collaborated and developed a solution combining both of their products enabling higher level of integration to improve patient safety and user comfort.

Supported by requirements & expertise of the Maastro Proton Therapy, both the companies aimed at creation of interface needed for uninterrupted workflow, including automated patient position correction & monitoring through the complete treatment process.

Chief Executive Officer at Mevion Medical Systems, Tina Yu stated that in keeping Mevion’s commitment to offer innovative services and products, the company is proud to collaborate with C-RAD to facilitate a fully integrated and advanced proton patient positioning surface to its customers.

CEO and President of C-RAD AB, Tim Thurn stated that accurate patient monitoring during and patient positioning before the treatment is vital in radiation therapies of high precision. This development is driving interest for the company’s top-notch surface tracking solutions.

Tim Thurn added that workflow optimization and user experience is getting important for company’s customers. C-RAD’s aim has always been to set a benchmark in workflow integration and usability. This project of Mevion and C-RAD would mark a new standard for the customers.

The Catalyst PT system is available for present as well as future customers of Mevion.

 

Source Credit:

https://www.biospace.com/article/releases/mevion-and-c-rad-release-integration-for-improved-treatment-quality-in-proton-therapy/



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Bio-Thera Solutions commences Phase 1 study for Simponi® biosimilar
Bio-Thera Solutions commences Phase 1 study for Simponi® biosimilar
By Paroma Bhattacharya

Bio-Thera Solutions, a China based pharmaceutical company, has reportedly announced the start of dosing of its first batch of healthy volunteers in order to compare the safety and pharmacokinetics of BAT2506, proposed ...

Amazon plans to open a brick-and-mortar liquor store in San Francisco
Amazon plans to open a brick-and-mortar liquor store in San Francisco
By Paroma Bhattacharya

  • The company is looking to launch a liquor shop in San Francisco for various alcoholic beverages.
     
  • Application for a liquor license and...

Astrazenca reveals positive results from Phase III trial of Lynparza
Astrazenca reveals positive results from Phase III trial of Lynparza
By Paroma Bhattacharya

Lynparza is a PARP inhibitor with promising Phase III results in ovarian breast pancreatic and prostate cancers.

AstraZeneca plc a biopharmaceutical company and MSD...